查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041736

藥物基因體學技術市場預測至2034年—按類型、治療領域、技術、分銷管道、最終用戶和地區分類的全球分析

Pharmacogenomics Technologies Market Forecasts to 2034 - Global Analysis By Type, Therapeutic Area, Technology, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球藥物基因體學技術市場規模將達到 92 億美元，並在預測期內以 10.7% 的複合年成長率成長，到 2034 年將達到 208 億美元。

藥物基因體學技術是指將藥理學和基因組學結合，根據個體的基因組成開發個人化醫療方案的領域。這些技術分析個體基因變異如何影響其對藥物的反應。透過了解這些基因變異，醫療專業人員可以更準確地預測患者對特定藥物的反應，確定最有效的劑量，並最大限度地降低副作用的風險。

根據美國癌症協會 2022 年的報告，預計 2022 年美國將診斷出 190 萬例新的癌症病例，其中 290,560 例為乳癌。

基因組技術的進步

基因測序和分析技術的進步正顯著推動市場擴張。次世代定序（NGS）、微陣列分析和生物資訊學工具能夠對與藥物反應相關的基因變異進行更全面的分析。這些創新有助於提高精準醫療水平，減少藥物處方中的試驗，並改善患者預後。

數據解讀的挑戰

分析基因數據十分複雜。尤其考慮到涉及的基因資訊量龐大，以臨床適用的方式解讀結果極具挑戰性。理解特定基因變異的意義及其對藥物反應的影響需要進行精密的分析。確保患者基因資訊的安全性和保密性至關重要，但這難以保證。這些因素正在阻礙市場成長。

對個人化醫療的需求日益成長

藥物基因體學技術透過基於個人基因譜最佳化治療方法，滿足了日益成長的個人化醫療需求。這種方法能夠提高藥物療效，最大限度地減少副作用，並為每位患者最佳化劑量。個人化醫療的重要性日益凸顯，它基於個別基因譜最佳化治療方法，從而促進藥物治療的個人化，最大限度地提高療效並最大限度地減少副作用。

監管和償還方面的挑戰

法律規範可能尚未充分準備好應對藥物基因體學，導致標準和指南方面存在不確定性。此外，基因檢測及相關服務的保險覆蓋範圍並非普遍覆蓋且缺乏標準化，這可能會限制部分患者的就醫機會。基因資料的定序、分析和解讀需要專門的設備和技術，且成本高。這些成本可能會阻礙藥物基因組學的廣泛應用和普及。

新冠疫情的影響：

新冠疫情加速了藥物基因體學研究，並凸顯了個人化醫療的重要性。了解遺傳因素如何影響藥物反應對於新冠肺炎治療方法和疫苗的研發至關重要。疫情期間遠端醫療的興起也影響了基因檢測和諮詢的進行方式。基因檢測和諮詢遠端醫療服務的廣泛應用，擴大了服務覆蓋範圍，並最大限度地減少了面對面接觸。

在預測期內，腫瘤學領域預計將擁有最大的市場規模。

在預測期內，腫瘤治療領域預計將成為最大的細分市場。其優點包括個人化治療方法選擇、最大限度減少副作用、最佳化藥物療效以及可預測的患者反應。這種根據個別基因譜客製化治療方案的精準方法，將改善治療效果，減少試驗，提高患者的生活品質，並使腫瘤治療朝著更有效、更個性化的方向發展。

在預測期內，醫院產業預計將呈現最高的複合年成長率。

在預測期內，醫院領域預計將呈現最高的複合年成長率。這種精準醫療方法能夠最大限度地減少副作用，提高藥物療效，並最佳化劑量。這減少了試驗錯處方箋，改善了患者預後，同時最大限度地降低了醫療成本。採用這些技術的醫院可以受益於個人化治療方案、減少副作用和簡化用藥策略，從而為患者提供更安全、更有效的醫療服務。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。高通量定序技術的進步使得分析個別基因資訊更加可行且經濟高效，從而促進了藥物基因體學在臨床領域的廣泛應用。人們日益認知到，根據個別基因譜客製化治療方案對於提高藥物療效和最大限度減少副作用至關重要。

複合年成長率最高的地區：

由於多種因素，包括醫療基礎設施投資的增加，預計亞太地區在預測期內將保持最高的複合年成長率。該市場涵蓋多種用於分析基因變異並輔助藥物研發、配方設計和劑量確定的技術，這些技術可根據個人基因譜進行客製化，例如DNA定序、微陣列技術、聚合酵素鏈鎖反應（PCR）和生物資訊工具。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球藥物基因體學技術市場：按類型分類

  • 生物資訊軟體
  • 臨床決策支援系統
  • 檢查資訊管理系統
  • 藥物基因體學學諮詢
  • 基因檢測服務
  • 樣品製備試劑盒
  • 其他類型

第6章：全球藥物基因體學技術市場：依治療領域分類

  • 神經病變
  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 子宮頸癌
    • 肺癌
  • 免疫系統疾病
  • 心血管疾病
  • 感染疾病
  • 其他治療領域

第7章 全球藥物基因體學技術市場：依技術分類

  • 定序
  • 免疫組織化學
  • 原位雜合反應
  • 聚合酵素鏈鎖反應（PCR）
  • 其他技術

第8章：全球藥物基因體學技術市場：按分銷管道分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第9章 全球藥物基因體學技術市場：依最終用戶分類

  • 醫院
  • 診所
  • 研究機構
  • 其他最終用戶

第10章 全球藥物基因體學技術市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Phamatech Inc
  • BiogeniQ Inc.
  • CENTOGENE NV
  • Empire Genomics
  • ViennaLab Diagnostics GmbH
  • Thermo Fisher Scientific
  • Admera Health
  • Agena Biosciences Inc.
  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Dynamic DNA Laboratories
  • Personalis Inc.
  • Coriell Life Sciences
  • Illunima Inc
  • OneOme LLC
  • QIAGEN
  • Leica Biosystems
Product Code: SMRC24799

According to Stratistics MRC, the Global Pharmacogenomics Technologies Market is accounted for $9.2 billion in 2026 and is expected to reach $20.8 billion by 2034 growing at a CAGR of 10.7% during the forecast period. Pharmacogenomics technologies refer to a field that combines pharmacology and genomics to develop personalized medicine based on an individual's genetic makeup. These technologies involve analyzing how an individual's genetic variations influence their response to medications. By understanding these genetic variations, healthcare providers can better predict how a person will respond to a particular drug, determine the most effective dosage, and minimize the risk of adverse reactions.

According to the American Cancer Society 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States in 2022, which includes 290,560 cases of breast cancer.

Market Dynamics:

Driver:

Advancements in genomic technologies

Progress in genomic sequencing and analysis technologies has significantly contributed to the expansion of market. Next-generation sequencing (NGS), microarray analysis, and bioinformatics tools enable more comprehensive analysis of genetic variations related to drug response. These innovations enhance precision medicine, minimizing trial and error in prescribing medications and improving patient outcomes.

Restraint:

Data interpretation challenges

Analyzing genetic data is complex. Interpreting the results in a clinically actionable way can be challenging, especially given the vast amount of genetic information involved. Understanding the implications of specific genetic variations and their impact on drug response requires sophisticated analysis. Ensuring the security and confidentiality of patient genetic information is critical but can be difficult to guarantee. These are the factors impeding the growth of the market.

Opportunity:

Increasing demand for personalized medicine

Pharmacogenomics technologies meet the rising demand for personalized medicine by tailoring treatments based on individual genetic profiles. This approach enhances drug efficacy, minimizes adverse reactions, and optimizes dosages for patients. There's a growing recognition of the importance of personalized medicine, which tailors treatments based on individual genetic profiles. It facilitates the customization of drug therapies to maximize efficacy and minimize adverse reactions.

Threat:

Regulatory and reimbursement challenges

Regulatory frameworks may not be fully equipped to handle pharmacogenomics, leading to uncertainties about standards and guidelines. Additionally, reimbursement for genetic testing and related services might not be universally available or standardized, limiting access for some patients. Sequencing, analyzing, and interpreting genetic data require specialized equipment and expertise, making the process costly. This expense can limit widespread adoption and accessibility.

Covid-19 Impact:

The pandemic has accelerated research in pharmacogenomics, emphasizing the importance of personalized medicine. Understanding how genetic factors influence drug response became crucial in developing treatments and vaccines for COVID-19. The shift towards telemedicine during the pandemic affected the way genetic testing and counseling was delivered. There's an increased use of telehealth services for genetic testing and consultations, allowing wider accessibility and minimizing in-person interactions.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to be the largest during the forecast period. Advantages include personalized therapy selection, minimizing adverse reactions, optimizing drug efficacy, and predicting patient response. This precision approach enhances treatment outcomes, reduces trial and error, and improves patient quality of life by matching therapies to individual genetic profiles, advancing oncology towards more effective and personalized care.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. This precision medicine approach minimizes adverse reactions, enhances drug efficacy, and optimizes dosage. It reduces trial-and-error prescribing, improving patient outcomes while minimizing healthcare costs. Hospitals employing these technologies benefit from personalized treatment plans, reduced side effects, and streamlined medication strategies, ensuring safer and more effective care for patients.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The development of high-throughput sequencing techniques has made it more feasible and cost-effective to analyze an individual's genetic information. This has enabled the widespread application of pharmacogenomics in clinical settings. There's a growing recognition of the importance of tailoring medical treatments to an individual's genetic profile to enhance drug efficacy and minimize adverse reactions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as increasing investments in healthcare infrastructure. The market involves various technologies such as DNA sequencing, microarray technology, polymerase chain reaction (PCR), and bioinformatics tools, among others, which are used to analyze genetic variations and aid in drug development, prescription, and dosage determination customized to an individual's genetic profile.

Key players in the market

Some of the key players in Pharmacogenomics Technologies market include Phamatech Inc, BiogeniQ Inc., CENTOGENE N.V., Empire Genomics, ViennaLab Diagnostics GmbH, Thermo Fisher Scientific, Admera Health, Agena Biosciences Inc., Myriad Genetics Inc., Quest Diagnostics, Dynamic DNA Laboratories, Personalis Inc., Coriell Life Sciences, Illunima Inc, OneOme LLC, QIAGEN and Leica Biosystems.

Key Developments:

In April 2023, Leica Biosystems received the clearance for BOND MMR Antibody Panel, which is expected to aid customers by offering the IHC Mismatch Repair (MMR) option when screening patients with colorectal cancer who may have Lynch syndrome.

In January 2023, QIAGEN announced a strategic partnership with Helix a population genomics company to aid companion diagnostics for genetic diseases.

Types Covered:

  • Bioinformatics Software
  • Clinical Decision Support System
  • Laboratory Information Management System
  • Pharmacogenomic Consulting
  • Genetic Testing Services
  • Sample Preparation Kits
  • Other Types

Therapeutic Areas Covered:

  • Neurological Disorders
  • Oncology
  • Immunological Disorders
  • Cardiovascular Disease
  • Infectious Diseases
  • Other Therapeutic Areas

Technologies Covered:

  • Sequencing
  • Immunohistochemistry
  • In-situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Other Technologies

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

End Users Covered:

  • Hospitals
  • Clinics
  • Research Institute
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Technologies Market, By Type

  • 5.1 Introduction
  • 5.2 Bioinformatics Software
  • 5.3 Clinical Decision Support System
  • 5.4 Laboratory Information Management System
  • 5.5 Pharmacogenomic Consulting
  • 5.6 Genetic Testing Services
  • 5.7 Sample Preparation Kits
  • 5.8 Other Types

6 Global Pharmacogenomics Technologies Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Neurological Disorders
  • 6.3 Oncology
    • 6.3.1 Breast Cancer
    • 6.3.2 Colorectal Cancer
    • 6.3.3 Cervical Cancer
    • 6.3.4 Lung Cancer
  • 6.4 Immunological Disorders
  • 6.5 Cardiovascular Disease
  • 6.6 Infectious Diseases
  • 6.7 Other Therapeutic Areas

7 Global Pharmacogenomics Technologies Market, By Technology

  • 7.1 Introduction
  • 7.2 Sequencing
  • 7.3 Immunohistochemistry
  • 7.4 In-situ Hybridization
  • 7.5 Polymerase Chain Reaction (PCR)
  • 7.6 Other Technologies

8 Global Pharmacogenomics Technologies Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Online Pharmacy

9 Global Pharmacogenomics Technologies Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Research Institute
  • 9.5 Other End Users

10 Global Pharmacogenomics Technologies Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Phamatech Inc
  • 12.2 BiogeniQ Inc.
  • 12.3 CENTOGENE N.V.
  • 12.4 Empire Genomics
  • 12.5 ViennaLab Diagnostics GmbH
  • 12.6 Thermo Fisher Scientific
  • 12.7 Admera Health
  • 12.8 Agena Biosciences Inc.
  • 12.9 Myriad Genetics Inc.
  • 12.10 Quest Diagnostics
  • 12.11 Dynamic DNA Laboratories
  • 12.12 Personalis Inc.
  • 12.13 Coriell Life Sciences
  • 12.14 Illunima Inc
  • 12.15 OneOme LLC
  • 12.16 QIAGEN
  • 12.17 Leica Biosystems

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pharmacogenomics Technologies Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Pharmacogenomics Technologies Market Outlook, By Bioinformatics Software (2023-2034) ($MN)
  • Table 4 Global Pharmacogenomics Technologies Market Outlook, By Clinical Decision Support System (2023-2034) ($MN)
  • Table 5 Global Pharmacogenomics Technologies Market Outlook, By Laboratory Information Management System (2023-2034) ($MN)
  • Table 6 Global Pharmacogenomics Technologies Market Outlook, By Pharmacogenomic Consulting (2023-2034) ($MN)
  • Table 7 Global Pharmacogenomics Technologies Market Outlook, By Genetic Testing Services (2023-2034) ($MN)
  • Table 8 Global Pharmacogenomics Technologies Market Outlook, By Sample Preparation Kits (2023-2034) ($MN)
  • Table 9 Global Pharmacogenomics Technologies Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 10 Global Pharmacogenomics Technologies Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 11 Global Pharmacogenomics Technologies Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 12 Global Pharmacogenomics Technologies Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 13 Global Pharmacogenomics Technologies Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 14 Global Pharmacogenomics Technologies Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 15 Global Pharmacogenomics Technologies Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 16 Global Pharmacogenomics Technologies Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 17 Global Pharmacogenomics Technologies Market Outlook, By Immunological Disorders (2023-2034) ($MN)
  • Table 18 Global Pharmacogenomics Technologies Market Outlook, By Cardiovascular Disease (2023-2034) ($MN)
  • Table 19 Global Pharmacogenomics Technologies Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 20 Global Pharmacogenomics Technologies Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
  • Table 21 Global Pharmacogenomics Technologies Market Outlook, By Technology (2023-2034) ($MN)
  • Table 22 Global Pharmacogenomics Technologies Market Outlook, By Sequencing (2023-2034) ($MN)
  • Table 23 Global Pharmacogenomics Technologies Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 24 Global Pharmacogenomics Technologies Market Outlook, By In-situ Hybridization (2023-2034) ($MN)
  • Table 25 Global Pharmacogenomics Technologies Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 26 Global Pharmacogenomics Technologies Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 27 Global Pharmacogenomics Technologies Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 28 Global Pharmacogenomics Technologies Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 29 Global Pharmacogenomics Technologies Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 30 Global Pharmacogenomics Technologies Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 31 Global Pharmacogenomics Technologies Market Outlook, By End User (2023-2034) ($MN)
  • Table 32 Global Pharmacogenomics Technologies Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 33 Global Pharmacogenomics Technologies Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 34 Global Pharmacogenomics Technologies Market Outlook, By Research Institute (2023-2034) ($MN)
  • Table 35 Global Pharmacogenomics Technologies Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.